Having a few ASX 200 blue-chip shares in your portfolio can be a good thing. That's because blue chips tend to be lower-risk options, which makes them a great foundation to build your investment portfolio from.
But which could be top options for a portfolio today? Let's see what analysts are recommending:
Cochlear Limited (ASX: COH)
The first ASX 200 blue-chip share to look at is Cochlear. It is a global leader in the development, manufacture, and distribution of cochlear implantable devices for the hearing impaired.
Thanks to its leadership position, wide distribution network, investment in research and development, and ageing populations, Cochlear has been growing at a solid rate for over a decade.
The good news is that all these factors remain in place today, which bodes well for the next decade.
It is partly for this reason that Goldman Sachs is bullish on the company and is forecasting a net profit after tax CAGR of +15% from FY 2023 to GY 2026.
Its analysts currently have a buy rating and a $280 price target on Cochlear's shares.
REA Group Limited (ASX: REA)
Another blue chip ASX 200 share that could be a buy is REA Group. It is the leading property listings company behind the dominant realestate.com.au website.
Thanks to this dominance, the shift to online listings, and its international expansion, REA Group has also been growing at a solid rate over the last decade.
Once again, Goldman Sachs appears confident this positive form can continue, particularly given its strong pricing power. It said: "We believe REA is among the highest-quality names in our coverage, given it has the highest ability to continue to drive pricing."
In light of this, Goldman has the company on its conviction list with a buy rating and a $175 price target.